News

dvm3602d
New immunotherapy treatment may delay metastasis in dogs with osteosarcoma
The immunotherapy OST-HER2 combined with palliative radiation has shown positive data in preventing or delaying amputation ...
Yahoo Finance7d
OS Therapies Incorporated (OSTX)
NEW YORK, April 09, 2025--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced ...
Seeking Alpha6d
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor ...
Nasdaq6d
OS Therapies Announces Positive Data From The Study Of OST-HER2 In Osteosarcoma In Dogs
(RTTNews) - OS Therapies Inc. (OSTX) Thursday announced positive data for OST-HER2 in combination with palliative radiation in dogs with unresected appendicular osteosarcoma. Results from the ...
Business Wire9d
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of ...
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC ...
Eagle-Tribune7d
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has ...
FY2025 EPS Forecast for OS Therapies Cut by Analyst
Equities researchers at Brookline Capital Management decreased their FY2025 earnings per share estimates for shares of OS Therapies in a research note issued to investors on Wednesday, April 2nd.
Investing7d
OS Therapies Inc secures shareholder nod for stock issuance
OS Therapies Inc, a Delaware-based pharmaceutical company trading at $1.34 per share with a market capitalization of $28.4 million, received approval from its shareholders for a significant stock ...
Investing7d
OS Therapies acquires Advaxis Immunotherapies assets
NEW YORK - OS Therapies (NYSE-A: OSTX), a biopharmaceutical company specializing in immunotherapy and Antibody Drug Conjugates (ADC), has announced the acquisition of listeria-based cancer ...
Seeking Alpha6d
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
"Based upon this initial research, OS Therapies conducted a successful translational Phase 2b clinical trial in the rare pediatric indication of prevention of recurrence of fully resected ...
Investing7d
OS Therapies Inc secures shareholder nod for stock issuance
OS Therapies Inc, a Delaware-based pharmaceutical company trading at $1.34 per share with a market capitalization of $28.4 million, received approval from its shareholders for a significant stock ...